Antiandrogenic Substances in the Management of Prostatic Cancer
- 1 January 1990
- book chapter
- Published by Springer Nature
- Vol. 118, 163-173
- https://doi.org/10.1007/978-3-642-83816-3_16
Abstract
Antiandrogens are substances which counteract the effect of exogenous or endogenous hormones at target cells independently of feedback mechanisms. Because of the difficulty in ruling out activity exerted due to the influence on feedback mechanisms, antihormones are usually tested under experimental conditions allowing the exclusion of feedback. In the example of antiandrogens this means that an antiandrogen is a substance which counteracts the effect of exogenous androgens in castrated animals. Antiandrogens probably exert their action at the target cell level by competing with androgens for receptor binding sites and by inhibiting the translocation of the hormone receptor complex into the nucleus (Neri 1977; Brinkmann et al. 1983).Keywords
This publication has 18 references indexed in Scilit:
- Flutamide as Primary Treatment for Metastatic Prostatic CancerBritish Journal of Urology, 1987
- Effect of cyproterone acetate in comparison to flutamide and megestrol acetate on the ventral prostate, seminal vesicle, and adrenal glands of adult male ratsThe Prostate, 1987
- Androgen levels in prostatic tissue of patients with carcinoma of the prostate treated with the combined therapy using an LHRH agonist and a pure antiandrogenEuropean Journal of Cancer and Clinical Oncology, 1986
- Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: A marked improvement in response and survivalJournal of Steroid Biochemistry, 1985
- Flutamide Therapy for Advanced Prostatic Cancer: a Phase II StudyBritish Journal of Urology, 1985
- Effect of Flutamide or Cyproterone Acetate on Pituitary and Testicular Hormones in Normal MenJournal of Clinical Endocrinology & Metabolism, 1984
- Antagonistic effect of androgen on prostatic cell deathThe Prostate, 1984
- Cyproterone acetate prevents translocation of the androgen receptor in the rat prostateMolecular and Cellular Endocrinology, 1983
- New approach in the treatment of prostate cancer: Complete instead of partial withdrawal of androgensThe Prostate, 1983
- A Biological Profile of a Nonsteroidal Antiandrogen, SCH 13521 (4'–Nitro–3'–Trifluoromethylisobutyranilide)1Endocrinology, 1972